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The following case reports illustrate two differing
presentations of pituitary apoplexy, and then
discuss appropriate investigation and treatment
options.
Case 1
Apreviouslyhealthy64-year-oldwomanpresented
to the emergency room with a three-day history of
feeling generally unwell, drowsiness and acute
onset, severe headache. She had a decreased level
of consciousness and a temperature of 39˚C. No
ophthalmoplegia, visual ﬁeld defect or other focal
neurological signs were present. She had a leucocy-
tosis and raised C-reactive protein (CRP) with
normal serum sodium. The chest radiograph was
unremarkable and computed tomography (CT) of
the brain was reported as showing involutional
changes. Analysis of cerebrospinal ﬂuid
demonstrated 220 red cells per μL, 408 white cells
per μL (83% polymorphs, 17% lymphocytes),
proteinorrachia 1.7 g/L (NR 0.1–0.4) glucose
1.8 mmol/L and xanthochromia. The patient was
presumed to have pneumococcal meningitis – the
commonest cause of bacterial meningitis in this
age group, and intravenous ceftriaxone was
administered.
Five days into admission the patient’s level of
consciousness was improving but not at baseline.
Severe headache and pyrexia continued. The cere-
brospinal ﬂuid was sterile. Further cranial
imaging was arranged and MRI scan demon-
strated a pituitary macroadenoma with evidence
of recent haemorrhage (Figure 1). Goldmann peri-
metry conﬁrmed intact visual ﬁelds. Hormone
tests revealed panhypopituitarism (cortisol
<30 nmol/L, thyroid-stimulating hormone [TSH]
<0.1 mU/L [0.27–4.2 mU/L], free thyroxine
15.2 pmol/L [9–20], free tri-iodothyronine
3.7 pmol/L [3.4–5.6], follicle-stimulating
hormone [FSH] and luteinizing hormone
[LH] <0.5 pmol/L, prolactin <47 mlU/L, growth
hormone [GH] <0.1 ug/L, insulin-like growth
factor-1 [IGF-1] 9.5 nmol/L [3.7–32.9]).
A diagnosis of pituitary apoplexy related to
haemorrhage with resultant hypopituitarism was
made. Hydrocortisone and thyroxine were com-
menced. After discussion with neurosurgical col-
leagues, it was agreed that operative intervention
was not required. The patient was discharged
home ﬁve days later. Although the patient contin-
ued to require pituitary replacement at follow-up
three years later, imaging showed a reduction in
the size of the pituitary mass.
Case 2
An 80-year-old man with history of hypertension
(requiring three antihypertensive agents) and
type 2 diabetes mellitus (managed with two oral
hypoglycaemic drugs) was admitted with a frac-
tured neck of femur following a low-trauma fall.
He was admitted to the orthopaedic ward to
await ﬁxation. However, he became hypotensive
and required ionotropic support and ﬂuid
resuscitation. His haemoglobin decreased (12.5 to
9.3 g/dl) and acute renal dysfunction developed.
The blood glucose was well controlled. A TSH in
the normal range (0.5 mU/L) was considered to
have ruled out myxoedema. Imaging excluded
thromboembolism and sepsis was clinically
unlikely. An echocardiogram demonstrated good
systolic function.
Four days after admission the patient was
considered ﬁt for hemiarthroplasty. Immediately
postoperatively he became hypoglycaemic (BM
DECLARATIONS
Competing interests
None declared
Funding
None
Ethical approval
Written informed
consent to
publication has been
obtained from the
patient or next of kin
Guarantor
SMH
Contributorship
SMH wrote Case 2
and edited the text;
JEC wrote Case 1
and the Discussion;
PVC and SMT were
involved with editing
and the ﬁnal drafts
Acknowledgements
None
Reviewer
Paul Grant
J R Soc Med Sh Rep 2010;1:53. DOI 10.1258/shorts.2010.100073
CASE REPORT
11.1 mmol/L) and progressively drowsy, with no
focal neurology, including visual ﬁelds. Hypona-
traemia and hypotension occurred. Full thyroid
function testing showed hypothyroidism (free
tri-iodothyronine 1.9 [3.4–5.6 pmol/L] and free
thyroxine 6.4 [9–20 pmol/L]) with an inadequate
pituitary response (TSH 1.0 mU/L [0.3–5.5])
prompting a diagnosis of pituitary apoplexy
leading to insufﬁciency. A brain CT scan
(Figure 2) showed macroadenoma with probable
haemorrhage. An MRI was recommended, but
due to his recent arthroplasty this could not be
performed safely.
A diagnosis of macroprolactinoma was con-
ﬁrmed with prolactin level 17543 mU/L (50–
480). Serum cortisol level was 47 nmol/L (120–
500) with ACTH undetectable. Endocrinology
team review concluded the patient had a chronic
pituitary adenoma, as evidenced from his long-
standing lack of testosterone (loss of secondary
sexual characteristics and osteoporosis), improv-
ing diabetic control (on review of clinic notes
HbA1c 7.6 in 2003 to 6.0 in 2005) and hyponatrae-
mia, with acute presentation secondary to
inability to mount a stress response.
Cabergoline, hydrocortisone and thyroxine
were introduced immediately (and testosterone
subsequently), and at review four years later
MRI conﬁrmed haemorrhage into macroadenoma,
now of reduced size, with controlled prolactin
level 190 nmol/L (on dopamine agonist
treatment).
Discussion
Pituitary apoplexy is a rare, under-diagnosed and
potentially fatal condition usually resulting from
haemorrhage or infarction of a pituitary
tumour.
1,2 In the majority of cases there is no
prior diagnosis of a pituitary tumour, increasing
the difﬁculty of diagnosing apoplexy.
3 Other pre-
disposing factors for apoplexy include anticoagu-
lant therapy, bleeding disorders, diabetes, head
injury, sudden changes in arterial or intracranial
pressure and postpartum haemorrhage.
1
Variability of clinical presentation poses a chal-
lenge. Leakage of infarcted tissue into the subar-
achnoid space may cause headache, altered level
of consciousness, visual disturbance, fever or
signs of meningism.
4,5 If the enlarged pituitary
or haemorrhage extends laterally into the caver-
nous sinus ophthalmoplegia may occur. Superior
expansion may cause visual impairment,
Figure 1
MRI brain showing a haemorrhagic lesion of the pituitary gland extending to the optic chiasm causing
displacement of the optic nerve, consistent with pituitary macroadenoma
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2classically a bitemporal hemianopia. If the acute
event is asymptomatic or subacute, patients
present later with symptoms of hormonal
deﬁciency.
6
Patients with pituitary apoplexy, meningitis
and subarachnoid haemorrhage can all present
with headache, impaired consciousness and
fever. To aid differentiation: pituitary apoplexy is
favoured by bilateral ocular nerve palsy or oph-
thalmological signs and/or extended interval
from headache to altered consciousness.
7 Bio-
chemical markers of pituitary insufﬁciency such
as cortisol deﬁciency should be sought and, as
illustrated, judicious biochemical assessment of
pituitary function is required. Although TSH is
often measurable, a diagnosis of secondary
hypothyroidism requires simultaneous measure-
ment of the free thyroid hormones. Whole-brain
imaging, especially CT, may obtain limited views
of the pituitary fossa restricting diagnostic sensi-
tivity. Thus, the gold standard modality is ‘pitu-
itary’ MRI, which also better delineates
haemorrhage.
5 Lumbar puncture is an important
investigation in all patients presenting with
fever, headache and impaired consciousness, but
this may not diagnose pituitary apoplexy, which
can show xanthochromia with raised red
cell count and/or raised white cell and protein
level.
8
The management of pituitary apoplexy
includes monitoring of ﬂuid and electrolytes as
secondary diabetes insipidus may occur.
5
Immediate high dose corticosteroid replacement
should be considered, and emergency surgical
decompression may be required in response to
diminished level of consciousness, visual impair-
ment or hypothalamic disturbance. Ocular
paresis is reported to resolve in all patients, with
acuity returning in 88% of cases.
5 Improved man-
agement of apoplexy has reduced mortality to 5%,
with 50% of patients requiring long-term pituitary
replacement therapy.
3,5
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